<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907452</url>
  </required_header>
  <id_info>
    <org_study_id>IFM 2007-03</org_study_id>
    <secondary_id>Eudract: 2008-003486-58</secondary_id>
    <nct_id>NCT00907452</nct_id>
  </id_info>
  <brief_title>Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone</brief_title>
  <official_title>Pharmacogenomic Study to Predict Survival, Best Response and Toxicity in Newly Diagnosed Myeloma Patients Above the Age of 65 Treated With Either a Combination of Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone du Myelome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone du Myelome</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol (in patients aged 65 and over suffering from previously untreated multiple
      myeloma), represents the first worldwide, pharmacogenomic study on this scale in terms of the
      number of patients analyzed and the implemented molecular diagnostics resources. The goal is
      to be able to identify patients who will best respond to the study treatments or experience
      the fewest associated side effects and improve prognosis, in order to optimize care
      management in multiple myeloma.

      To this end, the study seeks to predict the following parameters in these patients:

        -  The treatment response and occurrence of adverse events linked to a
           lenalidomide-dexamethasone combination or a melphalan-prednisone-thalidomide
           combination.

        -  Progression-free survival and overall survival.

      Prediction of the treatment response and the occurrence of adverse effects will be based on:

        -  An analysis of constitutive genetic traits linked to single nucleotide polymorphisms and
           DNA copy number variations.

        -  An analysis of changes in the tumor's genotype (change in the DNA copy number) and
           phenotype (altered gene and micro-RNA expression).

      Prediction of progression-free survival and overall survival will be based on an analysis of
      changes in the tumor's genotype and phenotype.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 29, 2009</start_date>
  <completion_date type="Actual">July 14, 2016</completion_date>
  <primary_completion_date type="Actual">December 14, 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>melphalan-prednisone-thalidomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>lenalidomide-dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan-prednisone-thalidomide</intervention_name>
    <arm_group_label>melphalan-prednisone-thalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide-dexamethasone</intervention_name>
    <arm_group_label>lenalidomide-dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand and voluntarily sign an informed consent form

          -  Age ≥ 65 years at the time of signing consent

          -  Previously untreated, symptomatic multiple myeloma as defined by the 3 criteria below:
             MM diagnostic criteria (all 3 required)

               -  Monoclonal plasma cells in the bone marrow ≥10% and/or presence of a
                  biopsy-proven plasmacytoma

               -  Monoclonal protein present in the serum and/or urine

               -  Myeloma-related organ dysfunction (at least one of the following):

                    -  Calcium elevation in the blood (serum calcium &gt; 10.5 mg/l or upper limit of
                       normal)

                    -  Renal insufficiency (serum creatinine &gt; 2 mg/dl)

                    -  Anemia (hemoglobin &lt; 10 g/dl or 2 g &lt; normal)

                    -  Lytic bone lesions or osteoporosis

          -  have measurable disease by protein electrophoresis analyses as defined by the
             following:

               -  IgG multiple myeloma: Serum monoclonal paraprotein (M-protein)level ≥ 1.0 g/dL or
                  urine M-protein level ≥ 200 mg/24 h

               -  IgA multiple myeloma: Serum M-protein level ³ 0.5 mg/dL or urine M-protein level³
                  200 mg/24 h

               -  IgM multiple myeloma (IgM M-protein plus lytic bone disease documented by
                  skeletal survey plain films): Serum M-protein level ≥ 1.0 g/dL or urine Mprotein
                  level ≥ 200 mg/24h

               -  IgD multiple myeloma: Serum M-protein level ≥ 0.05 g/dL or urine M-protein level
                  ≥ 200 mg/24h

               -  Light chain multiple myeloma: Serum M-protein level ≥ 1.0 g/dL or urine Mprotein
                  level ≥ 200 mg/24 hours

          -  ECOG performance status of 0, 1, or 2

          -  Treated by either melphalan-prednisone-thalidomide or lenalidomide- dexamethasone

        Exclusion Criteria:

          -  Previous treatment with antimyeloma therapy (does not include radiotherapy,
             bisphosphonates, or a single short course of steroid [i.e., less than or equal to the
             equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid
             treatment must not have been given within 28 days (4 weeks) of randomization]

          -  Any serious medical condition that places the patient at an unacceptable risk if he or
             she participates in this study

          -  Any of the following laboratory abnormalities :

               -  Absolute neutrophil count (ANC) &lt; 1,000 cells/µL (1.0 x 109/L)

               -  Platelet count &lt; 50,000 cells/µL (50 x 109/L) for patients in whom &lt; 50% of bone
                  marrow nucleated cells are plasma cells; but platelet count &lt; 30,000/µL for
                  patients in whom ≥ 50% of bone marrow nucleated cells are plasma cells

               -  Serum SGOT/AST or SGPT/ALT &gt; 3.0 x upper limit of normal (ULN)

               -  Creatinine clearance ≤ 30 mL/min (Cockroft-Gault calculation)

          -  Prior history of malignancies, other than multiple myeloma, unless the subject has
             been free of the disease for ≥ 3 years. Exceptions include the following:

               -  Basal cell carcinoma of the skin

               -  Squamous cell carcinoma of the skin

               -  Carcinoma in situ of the cervix

               -  Carcinoma in situ of the breast

               -  Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)

          -  Patients who have are unable or unwilling to undergo antithrombotic therapy

          -  Peripheral neuropathy of &gt; grade 2 severity

          -  Known HIV positivity or active infectious hepatitis, type A, B, or C.

          -  Primary AL amyloidosis and myeloma complicated by amyloidosis.

          -  Renal failure requiring dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe MOREAU, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Departement of clinical Hematology (University Hospital of Nantes)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH ALBI</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Côte basque</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Blois</name>
      <address>
        <city>Blois</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BORDEAUX</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chalons sur Saone</name>
      <address>
        <city>Chalons Sur Saone</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU LYON</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LYON SUD</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipc Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR METZ</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine LACASSAGNE</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Yves Le Foll</name>
      <address>
        <city>St Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>René Huguenin</name>
      <address>
        <city>St CLOUD</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 20, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2009</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <name_title>Principal investigator: AVET-LOISEAU Hervé</name_title>
    <organization>University Hospital, Nantes</organization>
  </responsible_party>
  <keyword>Pharmacogenomics</keyword>
  <keyword>prediction response</keyword>
  <keyword>prediction adverse event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

